Retrospective evaluation of efficacy of CytoSorb® therapy in septic shock patients in a tertiary care intensive care unit

Figure 1 Pathophysiology of septic shock. PAMPs: Pathogen-associated molecular Patterns; DAMPs: Damage-associated molecular patterns; PMN: Polymorphonuclear neutrophils; TNF: Tumor necrosis factor; IL: Interleukin; TGF: Transforming growth factor; HAI: Healthcare-associated infections; MODS: Multiple organ dysfunction syndrome.

Figure 2 Key features of the cytoSorb therapy. A: CytoSorb adsorber-bead based technology; B: CytoSorb size selective removal.

Figure 3 Sepsis severity and prognosis. A: Delta lactate score classification; B: Comparison of sepsis scores; C: Delta sepsis associated organ failure score classification. SOFA: Sepsis Associated Organ Failure; APACHE II: Acute Physiology and Chronic Health Evaluation; PRE: Values recorded pre/before CytoSorb; POST: Values recorded post/after CytoSorb.

Figure 4 Time to initiate CytoSorb after intensive care unit admission. ICU: Intensive care unit.

Figure 5 Treatment flowchart[11,21,29]. SOC: Standard of Care; NE: Norepinephrine; IL: Interleukin.